It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
[...]its longitudinal progression should be further evaluated for appropriate management and counseling of patients. Table 3 Treatment and Outcome Directed therapy (N = 32, 78.0%) Long-acting inhaler, N (%) 27 (84.4) Systemic corticosteroids, N (%) 10 (31.3) Macrolides, N (%) 18 (56.3) Oxygen supplementation at rest Less than or equal to 3 L O2, N (%) 4 (12.5) Greater than 3 L, N (%) 1 (3.1) Transplantation, N (%) 1 (3.1) Mortality, N (%) 11 (26.8) Time from OB diagnosis to death, months (mean ± SD) 54 ± 53 Table 4 Univariable Cox regression predictors of all-cause mortality Characteristics HR (95% CI) P-value Age at diagnosis, years 0.99 (0.94–1.05) 0.78 Gender, female 0.93 (0.15–17.6) 0.94 Duration of RA prior to diagnosis, years 0.98 (0.94–1.03) 0.58 Active joint symptoms at diagnosis 1.87 (0.24–11.42) 0.51 Mosaic attenuation at diagnosis 0.59 (0.12–2.17) 0.44 Lung fibrosis at diagnosis 2.12 (0.58–7.76) 0.24 Bronchiectasis at diagnosis 1.02 (0.28–3.69) 0.97 Baseline PFTs at diagnosis TLC% 0.99 (0.95–1.04) 0.76 RV/TLC% 1.01 (0.98–1.03) 0.51 FVC% 0.94 (0.87–1.03) 0.19 FEV1% 0.99 (0.91–1.07) 0.96 Positive bronchodilator response 3.41 (0.73–17.7) 0.11 Macrolide therapy 1.73 (0.40–7.44) 0.44 Abbreviations: TLC% percent of predicted total lung capacity, RV/TLC% percent of predicted residual volume over total lung capacity, FVC% percent of predicted forced vital capacity, FEV1% percent of predicted forced expiratory volume in the first second, RA rheumatoid arthritis Discussion To our knowledge, this study represents the largest case series to date of patients with rheumatoid arthritis-associated obliterative bronchiolitis. Patients also had physiologic studies measured at varied intervals over time which make accurate assessment of rates of decline less reliable over the study interval. Because of the lack of standardized therapy, we were unable to make inferences about the efficacy of any particular treatment regimen on pulmonary function testing or clinical course. [...]as a retrospective study, exact circumstances involved in decision making are difficult to determine, particularly causal effects of management.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer